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This article refers to ‘Physiological dead space and arte-
rial carbon dioxide contributions to exercise ventilatory
inefficiency in patients with reduced or preserved ejection
fraction heart failure’, by E.H. Van Iterson et al., published
in this issue on pages 1675–1685.
A progressive increase in exercise ventilation (VE) is vital to the
efficiency of gas exchange and its related abnormalities have been
long recognized as a matter of concern in heart failure (HF).1
At sea level (normobaric normoxia) VE is regulated by the car-
bon dioxide production (VCO2), the dead space to tidal volume
ratio (VD/VT), and the CO2 partial pressure (PaCO2), which are
the final bioproduct of muscle activity, waste VE, and chemoreflex
regulation, respectively. Accordingly, VE increases during exercise
due to the progressive release of CO2 and their relationship
is determined by two sources based on the modified alveolar
equation (Figure 1A): the increased VE, which is required to over-
come a large dead space to maintain a normal PaCO2, and the
enhanced neural drive to VE which yields PaCO2 levels below
what is normally expected. In healthy individuals, for low to mod-
erate intensity of work, the VE response is tightly regulated by the
PaCO2, whereas at higher work intensities, VE is more affected
by the amount of VD/VT and by the development of lactic acido-
sis and H+ production from anaerobic prevailing metabolism. In its
turn, VD/VT is highly dependent on respiratory rate. Thus, VD/VT
ratio and PaCO2 are the two reference variables for exploring the
pathways involved in a deranged ventilatory response.2
The physiological increase in exercise VE during a ramp exercise
protocol to maximum is defined by four distinct phases: the
first up to the ventilatory threshold, also called the anaerobic
threshold; the second between the 1st ventilatory threshold and
the respiratory compensation point (2nd ventilatory threshold);
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. the third up to peak exercise. In a few highly performing subjects
a fourth phase is observed around peak exercise (Figure 1B). The
mediators of these phases are VO2, VCO2, unbuffered acidosis,
and thermal dispersion, respectively. All these factors are, at least
in part, under the control of the sympathetic nervous system.
The net result of changes in VE during exercise is defined by the
VE/VCO2 relationship that in normal conditions is characterized
by an intercept at 4–5 L and for an approximately 1 L of VCO2
by 23–25 L/min VE (Figure 1B). Overall, VE/VCO2 reflects VE
efficiency, which is similarly described when assessing the ratio at
determined points (1st ventilatory threshold or lower ratio) or
the slope.3
In HF, there are a number of factors that may mutually and neg-
atively interact impairing this relationship during exercise: intrinsic
pulmonary vascular4 and non-vascular disease,5–7 impaired neural8
control of VE, and early incurrence of acidosis (Figure 1C).7 Over-
all, it is now well established that an excessive VE during exercise,
i.e. steep VE/VCO2 slope, is the net result of the deregulated
cardiorespiratory reflex control and a manifestation of structural
changes in the lung that impair ventilation (V)/perfusion (Q) match-
ing. In their pioneering report, Wasserman et al.5 showed that in
HF with reduced ejection fraction (HFrEF) VE is increased for a
given work rate, even double than in normal subjects.
What are the reasons and related interpretations? Again, from
a physiological standpoint, it is relevant to define ‘hyperpnoea’
(increase in VE response at normal PaCO2) compared with ‘hyper-
ventilation’ (increase in VE at PaCO2 levels below normal). In
the former case, VD/VT is the cause of the increased VE for a
given VCO2 while reflex, sympathetic-induced, increase in VE is
present, alone or combined with VD/VT increase, in the second
case. In HFrEF it has been shown that 8%, 47%, and 45% of VE
increase is due to PaCO2, VCO2, and VD/VT, respectively.
5 This,
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Figure 1 (A) The modified alveolar equation and its determinants. (B) Description of ventilation vs. carbon dioxide production increase during
exercise. Ventilation increments are driven by CO2 changes in the deoxygenated blood. A difference between alveolar ventilation and effective
ventilation increase is mediated by the extent of dead space. After a linear increase in the initial and intermediate phases, a change in slope
occurs due to isocapnic compensation for incoming acidosis. At the end of exercise, a further steepening occurs as a result of respiratory
compensation. Adapted with permission from Principles of Exercise Testing and Interpretation, Wasserman et al.,30 Lippincott Williams & Wilkins
©2011. (C) Mechanisms responsible for the increase in ventilation/carbon dioxide production slope during exercise in heart failure. PaCO2,
CO2 partial pressure; PVR, pulmonary vascular resistance; VA, alveolar ventilation; VCO2, carbon dioxide production; VD, dead space; VE,
ventilation; VT, tidal volume.
along with other evidence, has made it axiomatic that HF patients
display a sort of mixed response due to either hyperpnoea or
hyperventilation.
Ultimately, an increased VE/VCO2 slope has long been recog-
nized as a major determinant of exercise limitation in HF and one
of the most powerful predictors of outcome available.9 Unequivo-
cal evidence on this parameter has yielded to the formulation of a
subdivision of four classes to be used and integrated in a multipara-
metric process of clinical decision-making.10–12 Thus, the precise
knowledge about what factor disturbs the exercise VE/VCO2 slope
translates into a better potential for treatment.13
Of note, most of the findings regarding the pathophysiological
and clinical insights on VE/VCO2 slope have been obtained in a
population of HFrEF.14
In the present issue of the Journal, Van Iterson et al.15 report
an elegant set of observations on the two pathophysiological
contributors to impaired VE efficiency during exercise, extending
the evidence to HF with preserved ejection fraction (HFpEF)
patients. Interestingly, a comparative evaluation of HFrEF vs. HFpEF
by cardiopulmonary exercise testing with PaCO2 sampling via radial .
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. arterial catheterization showed an impaired VE efficiency in both
groups, despite a higher level of VE/VCO2 slope in HFrEF, and a
different pattern in VD/VT and PaCO2.
At rest, HFrEF, compared with HFpEF, displayed an end-tidal
CO2 (PETCO2) significantly lower (for the same respiratory rate),
consistent with a tendency toward a lower PaCO2 and a higher
VD/VT, which is indicative of more ventilated but not perfused
lung areas. The same was observed at peak exercise with the
new finding that HFpEF is accompanied by a predominant impair-
ment of VD/VT and a quite normal PaCO2, suggestive, from a
physiological point of view, of hyperpnoea. This pattern clearly dif-
ferentiates HFpEF from HFrEF whose abnormal VE response is
also driven by a low PaCO2 and increased chemoreflex activity
(hyperventilation).16–18 The unquestionable strength of the paper
is the reliable measurement of VD/VT by incorporating into the
formula the invasively obtained PaCO2 and avoiding the underesti-
mation when calculated by PETCO2.
19
Some considerations are necessary to better highlight the
present findings. Is there enough evidence for abnormal VE to
play a critical role in HFpEF? How could the differences in VE
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determinants be convincingly explained and what are the potential
reasons for a prevailing VD/VT-related mechanism in HFpEF?
HFpEF definition applies to a garden-variety of clinical pheno-
types. Previous studies have reported lower levels of inefficient
VE compared with the present population.20,21 Nonetheless, the
actual population appears to be in a quite peculiar advanced stage
of the syndrome as suggested by the high rate (74%) of Weber
peak VO2 class D.
As VD/VT depends on V/Q mismatch, valid measures of V/Q
matching are helpful for the identification of underlying mecha-
nisms and provide clear implications in terms of interventions.
Actually, measures of alveolar gas diffusion would have been of help
in this respect. Nonetheless, the authors make a strong argument
on the minimal effect that a mild reduction in alveolar gas diffusion
(around 20% based on a previous case series) would have on CO2
transfer even in the presence of a low perfusion, while impacting
the alveolar–arterial O2 difference. Thus, a lung vascular disease,
potentially induced by the systemic proinflammatory state22, may
be suspected to play the major role in the present HFpEF popula-
tion. Very likely, this assertion would have been less speculative in
the case of a direct lung V/Q assessment23 along with a thorough
definition of the underlying pulmonary haemodynamics and right
ventricular function to pulmonary circulation coupling.24
Considering the different underlying pathophysiology, with a pre-
vailing higher reflex-induced inefficiency of VE in HFrEF as the
major reason for exercise hyperventilation and a high VD/VT as
the major cause of hyperpnoea in HFpEF, should we start to con-
sider ventilatory abnormalities during exercise a more focused tar-
get of therapy and treat them accordingly? Evidence is lacking but
some speculation may derive from the observed physiological ven-
tilatory adaptations obtained at high altitude, where hypoxia (and
the associated high VE/VCO2 slope) can be partially corrected by
a voluntarily imposed high tidal volume at low VE frequencies.25
This way of breathing is typical of some relaxing activities such as
rosarium, yoga, and listening to music that might overall benefit VE
efficiency, at least in HFrEF.26,27 In HFpEF, the recent greater molec-
ular understanding of endothelial damage and oxidative stress due
to the proinflammatory state would imply the concept of a pul-
monary microvessel vasculopathy susceptible to benefits by inter-
ventions targeting the impaired nitric oxide–cGMP bioavailability
pathway by improving the regional lung perfusion and, for instance,
the VD/VT pattern during exercise.28,29
In conclusion, evidence provided by Van Iterson et al.15 refreshes
some knowledge on the ventilatory mediators of exercise intol-
erance and remarkably enriches the picture, especially prospect-
ing for new insights on patients with HFpEF. Findings support the
hypothesis that HFpEF and HFrEF may be two distinct entities also
in terms of ventilatory response to physical challenge. The roadmap
of HFpEF phenotyping is intriguingly moving forward, hopefully in
the right direction.
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